Clinical Trial Update: Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. [Phase 2]

View source ↗

Summary

Enzastaurin was studied as a second- or third-line treatment for non-small cell lung cancer in a Phase 2 trial, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Enzastaurin (enzastaurin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED